Table 5.
Pre- and post-implementation categorization of the FILDCARE Project participants according to set criteria of the clinical endpoints
| Proportions, n (%) | |||||
|---|---|---|---|---|---|
|
| |||||
| Clinical endpoints | Reference values | Pre-implementation | Post-implementation | p Value (test of proportions) | |
| Glycosylated hemoglobin (%) | |||||
| Good glycemic control | All | <7.0% | 61 (37.2%) | 83 (50.6%) | 0.014 |
| Batac | 38 (35.2%) | 54 (50.0%) | <0.001 | ||
| Pagudpud | 23 (41.1%) | 29 (51.8%) | 0.034 | ||
| Body mass index classification (kg/m2) | |||||
| Underweight | <18.5 | 6 (3.7%) | 11 (6.7%) | 0.213 | |
| Normal | 18.5–22.9 | 59 (36.0%) | 65 (39.6%) | 0.494 | |
| Overweight | 23–24.9 | 45 (27.4%) | 35 (21.3%) | 0.199 | |
| Obese type 1 | 25–29.9 | 47 (28.7%) | 46 (28.1%) | 0.902 | |
| Obese type 2 | ≥30 | 7 (4.3%) | 7 (4.3%) | 1.000 | |
| Waist circumference risk stratification (cm) | |||||
| Low risk | Male <90 cm Female <80 cm | 53 (32.3%) | 61 (37.2%) | 0.354 | |
| Waist-hip ratio risk stratification | |||||
| Low risk | Male ≤0.95 Female ≤0.80 | 40 (24.4%) | 0.286 | ||
| Moderate risk | Male=0.96–1.0 Female=0.81–0.85 | 31 (18.9%) | 33 (20.1%) | 0.781 | |
| High risk | Male >1.0 Female >0.85 | 102 (62.2%) | 91 (55.5%) | 0.217 | |